Drug Discovery World

OCTOBER 25, 2023

By characterising these resistance mechanisms, iOnctura is designing novel, safe combination treatments that promise to override resistance. The post New research highlights potential of combination cancer treatment appeared first on Drug Discovery World (DDW).

Treatment 130

Treatment Research Clinical Development Therapies 130

Drug Discovery World

FEBRUARY 1, 2024

At present there is no cure for CTX, only treatment to slow disease progression. The funding programme Vivet will use the funds to further develop its gene therapy product VTX-806 as an effective treatment option to stop or reverse disease progression over the long-term, or potentially cure CTX in patients.

Therapies 130

Therapies Treatment Disease Virus 130

Drug Discovery World

JUNE 21, 2023

Citius Pharmaceuticals has revealed positive results from its Phase IIb Study of Halo-Lido (CITI-002) for the treatment of haemorrhoids. Following the 21 st Century Cures Act, higher emphasis is placed on using Patient Reported Outcome (PRO) instruments in clinical trials.

Treatment 130

Treatment Trials Clinical Trials Clinical Development 130

Drug Discovery World

DECEMBER 5, 2023

Cancer Research UK (CRUK), Cancer Research Horizons, and precision oncology company Guardant Health have launched a collaboration to advance cancer treatment. The post CRUK and Guardant Health collaborate on precision cancer drugs appeared first on Drug Discovery World (DDW).

Clinical Trials 286

Clinical Trials Drugs Trials Clinical Development 286

Fierce BioTech

JULY 19, 2023

From drug discovery to study conduct, industry experts will delve into key areas of transformation, including study start-up, study design, and process optimization. Accelerating time to treatment. Don't miss this opportunity to gain valuable insights and explore the future of clinical development.

Clinical Development 52

Clinical Development Science Pharmaceuticals Treatment 52

Drug Discovery World

JANUARY 25, 2024

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Pleco Therapeutics’s lead compound PTX-252 for the treatment of acute myeloid leukaemia (AML). PTX-252 is a novel molecular entity developed to increase the sensitivity of cancer cells to chemotherapy. cases per 100,000 population, Globocan).

FDA 130

FDA Drugs Clinical Trials Clinical Development 130

Drug Discovery World

SEPTEMBER 4, 2024

Evommune’s pre-clinical data demonstrates that by blocking activation of MRGPRX2 via all disease relevant ligand categories, EVO756 can prevent the degranulation of mast cells. “As we continue to execute on our clinical development plans for EVO756, we are commencing this Phase II trial in 15 study sites across the United States.

Clinical Trials 130

Clinical Trials Trials Small Molecule Clinical Development 130

Drug Discovery World

SEPTEMBER 14, 2023

6,7 “For patients with advanced UC, including FGFR-driven tumours, outcomes remain poor and treatment options are limited; therefore, there is a need for novel, targeted therapies,” said Martin Vogel, EMEA Therapeutic Area Lead Oncology, Janssen-Cilag GmbH. “We References Wong MCS, et al.

Treatment 130

Treatment Clinical Pharmacology FDA Approval Therapies 130

Drug Discovery World

OCTOBER 11, 2022

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new class of treatment for adults with insufficiently controlled type 2 diabetes. . It is the first GIP and GLP-1 receptor agonist authorised for the treatment of adults with type 2 diabetes in Great Britain. .

Treatment 130

Treatment Clinical Development Production Marketing 130

Drug Discovery World

FEBRUARY 26, 2024

The US Food and Drug Administration (FDA) has granted Fast Track Designation for Certa Therapeutics’ investigational therapy FT011 for the treatment of systemic sclerosis (scleroderma). The post Scleroderma drug gets fast-tracked in the US appeared first on Drug Discovery World (DDW).

Clinical Trials 130

Clinical Trials Drugs Therapies Treatment 130

Drug Target Review

JUNE 9, 2023

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

Drug Discovery World

NOVEMBER 30, 2023

Treatment with FT011 for 12 weeks resulted in a clinically meaningful improvement in 60% of patients treated with FT011 400mg and 20% of patients in the FT011 200mg group compared with 10% in the placebo group. I look forward to collaborating with the company in the FT011 development program ahead.”

Drug Trials 147

Drug Trials Trials Clinical Trials Drugs 147

Drug Target Review

OCTOBER 11, 2023

More than 7,000 rare diseases – conditions that affect fewer than 1 in 2,000 people – have been identified, and1 in 17 people will develop a rare disease in their lifetime, with children disproportionately affected. Most of these conditions are genetic in origin and the majority have no effective treatment.

Disease 113

Disease Treatment Small Molecule Therapies 113

Drug Discovery World

MARCH 15, 2024

We are excited to begin the next phase of development with the initiation of two 28-day patient studies, the first studies of ALX-001 in people living with Alzheimer’s and Parkinson’s disease,” commented Tim Siegert, Chief Operating Officer and Co-Founder of Allyx Therapeutics. “We

Disease 130

Disease Trials Small Molecule Pharmacokinetics 130

Drug Discovery World

JUNE 26, 2024

Biotechnology company EG 427 has revealed plans to start a Phase Ib/IIa clinical study in neurogenic detrusor overactivity (NDO), following Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA).

Therapies 147

Therapies Clinical Development Disease FDA 147

Drug Discovery World

SEPTEMBER 6, 2024

The trial is being run by NH TherAguix, a biotechnology company developing novel nanomedicine solutions for precision radiotherapy in oncology, and is managed by the Dana Farber Cancer Institute.

Trials 130

Trials Clinical Trials Clinical Development Hospitals 130

Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Research into new cancer drugs remain strong.

Drug Development 162

Drug Development Research Clinical Trials Drugs 162

Drug Discovery World

APRIL 18, 2023

Avacta Group has presented pre-clinical data describing the novel pre|CISION proteasome inhibitor, AVA3996, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Florida, US. Proteasome inhibitors are effective anti-cancer drugs that could benefit from application of our preICISION technology to expand their use.

Therapies 242

Therapies Clinical Development Treatment Marketing 242

Drug Discovery World

JULY 26, 2023

A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. The drug, MOv18 IgE, was developed by researchers at King’s College London.

Clinical Trials 130

Clinical Trials Immune Response Drugs Trials 130

Drug Discovery World

JULY 12, 2024

The US Food and Drug Administration (FDA) has granted Fast Track Designation for Asklepios BioPharmaceutical’s (AskBio) AB-1005 which is being developed for moderate Parkinson’s disease. AB-1005 is an investigational adeno-associated virus 2 glial cell line-derived neurotrophic factor (AAV2-GDNF) neurorestorative gene therapy.

Therapies 147

Therapies Clinical Trials FDA Clinical Development 147

Drug Discovery World

JULY 5, 2024

Newron Pharmaceuticals has reported new findings of mechanism of action that indicate its drug candidate evenamide could be uniquely effective in patients with treatment resistant schizophrenia (TRS).

Pharmaceuticals 264

Pharmaceuticals Clinical Development International Therapies 264

Drug Discovery World

MARCH 18, 2024

In the five JNJ-2113 treatment groups, as measured by the Psoriasis Area and Severity Index (PASI), response rates were maintained from Week 16 to Week 52, with the highest PASI 75 response observed in the 100mg twice daily group.

Clinical Trials 130

Clinical Trials Drugs Trials Clinical Development 130

Drug Discovery World

JULY 21, 2023

Madrigal Pharmaceuticals has submitted an application for resmetirom, a drug for nonalcoholic steatohepatitis (NASH) with liver fibrosis, to the US Food and Drug Administration (FDA) and has requested a priority review. The post First drug for NASH with liver fibrosis submitted to FDA appeared first on Drug Discovery World (DDW).

FDA 130

FDA Drugs Clinical Development Pharmaceuticals 130

Drug Discovery World

APRIL 22, 2024

The discovery of two genes responsible for sensing the environment and adapting cell shape could offer potential new drug targets to stop cancer from metastasising. These genes are good candidates for drug discovery as they have a structure similar to other proteins for which drugs are already in pre-clinical development.

Drugs 130

Drugs Laboratories Research Clinical Development 130

Drug Discovery World

JANUARY 12, 2023

This license allows us to accelerate a promising drug target towards clinical development,” said Fraser Murray, Chief Executive Officer of Pheno Therapeutics. . The post Pheno Therapeutics buys rights to potential remyelination drug appeared first on Drug Discovery World (DDW).

Small Molecule 130

Small Molecule Licensing Licensing Drugs 130

Drug Discovery World

JUNE 27, 2023

The US Food and Drug Administration (FDA) has published new draft guidance to highlight fundamental considerations to researchers investigating the use of psychedelic drugs for the potential treatment of medical conditions, including psychiatric or substance use disorders. However, these are still investigational products.

Drug Development 130

Drug Development FDA Clinical Trials Drugs 130

Drug Discovery World

SEPTEMBER 12, 2024

The company develops hybrid interferons, a new drug class engineered for improved therapeutic profiles across multiple indications. The money will support the continued pre-clinical development of the company’s two lead assets, Alfacyte and Dermacyte, as they move towards the clinic.

Virus 147

Virus Engineering Clinical Development Drug Development 147

Drug Discovery World

MARCH 28, 2023

iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, has been awarded the innovative medicine designation, the Innovation Passport, for roginolisib, for the treatment of metastatic uveal melanoma by the Medicines & Healthcare products Regulatory Agency (MHRA).

Drugs 130

Drugs Clinical Development Therapies Production 130

Drug Discovery World

FEBRUARY 10, 2023

Clinical drug trials have made the headlines this week, as it was revealed that breast cancer still tops the bill for number of clinical studies and the shortcomings in current methods to ensure representation of patient populations in trials were exposed.

Clinical Trials 130

Clinical Trials Trials Drugs Vaccine 130

Drug Discovery World

AUGUST 21, 2024

Adcendo and Multitude Therapeutics have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF) with the development code ADCE-T02.

Licensing 130

Licensing Licensing Clinical Development Clinical Trials 130

Drug Discovery World

MARCH 10, 2023

Cancer Research UK and UCB have agreed a clinical development collaboration to advance two of UCB’s investigational oncology antibody candidates through clinical trials. If successful in clinical trials the investigational candidates may have the potential to offer cancer patients access to new targeted treatment options.

Research 246

Research Clinical Trials Clinical Development Trials 246

The Pharma Data

DECEMBER 14, 2020

AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01. In parallel, AlgoTx firmed-up ATX01’s development pathway via a pre-IND consultation with the FDA and obtained an Orphan Drug Designation from the FDA to explore ATX01’s activity in erythromelalgia.

Clinical Development 52

Clinical Development Clinical Supply Pharmacokinetics Packaging 52

Drug Discovery World

JULY 18, 2023

Among the 73 genes, 42 have potential for novel drug discovery approaches, with 13 of these already targeted by drugs in clinical development pipelines. The post Ground-breaking study identifies novel drug targets for long Covid appeared first on Drug Discovery World (DDW).

Drugs 130

Drugs Disease Clinical Development Treatment 130

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1.

Marketing 245

Marketing FDA Approval Licensing Licensing 245

Drug Discovery World

MARCH 7, 2024

Following closing, the company will have an expanded pipeline that contains multiple assets spanning early and late development stages. The merged pipeline features an antibody-drug conjugate (ADC) toolkit with novel payload and linker technologies.

Clinical Trials 147

Clinical Trials Licensing Licensing Clinical Development 147

Drug Discovery World

FEBRUARY 27, 2023

Under a new agreement, Destiny Pharma and Sebela Pharmaceuticals will co-develop NTCD-M3, Destiny’s lead asset for the prevention of Clostridioides difficile infection (CDI) recurrence. NTCD-M3 temporarily colonises the human gut without causing any symptoms and the gut microbiome returns to normal a few weeks after treatment.

Clinical Trials 130

Clinical Trials Licensing Licensing Drugs 130

Drug Discovery World

JUNE 27, 2023

Together, the three institutions, in collaboration with Therapeutic Innovation Australia (TIA), will guide early-stage projects through the process of identifying drug candidates with potential commercial value. The capacity gap MedChem Australia will help to fill a significant capacity gap in the drug discovery pipeline.

Drugs 130

Drugs Medical Chemistry Pharmacokinetics Science 130